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Inflammation contributes a significant part to the advancement of diabetic kidney disease (DKD), yet relatively 
little is known about the root cause of these inflammatory events. Serum Amyloid A (SAA) triggers a potent 
inflammatory response in a variety of tissues and is up-regulated in glomerular and tubulointerstitial 
compartments of the diabetic kidney. Under inflammatory conditions, podocytes, along with other intrinsic cells, 
produce SAA locally in the kidney. Our recent work has shown that SAA induces NF-κB activation and 
subsequent inflammatory chemokines and cytokines in cultured podocytes. Recent evidence suggests that local 
production of SAA in diabetes may lead to monocyte and macrophage recruitment, neutrophil activation, and 
other related incidents resulting in sustained chronic inflammatory conditions in the kidney which may further 
exacerbate DKD. 
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SAA in diabetic kidney disease 
Diabetic kidney disease (DKD) is recognized as an 
inflammatory disease due to robust evidence that leukocytes 
are recruited to and cause injury in kidney tissue of patients 
with DKD [1, 2]. Acute-phase serum amyloid A (SAA) has 
been implicated in promoting inflammation in a variety of 
tissues [3-5]. We have recently demonstrated that SAA is 
elevated in the plasma and kidneys of both people with DKD 
and analogous mouse models [3]. A mechanism for this could 
be production of SAA by exposure of the kidney, and other 
tissues and organs, to advanced glycation end products 
(AGE), anomalous metabolic by-products that are elevated in 
the diabetic state and promote oxidative stress and 
inflammation [6-8]. Our research has shown that AGE induce 
SAA up-regulation in glomerular podocytes through the 
advanced glycation end product receptor (RAGE) [8]. This 
receptor is responsible for initiation of a variety of 
inflammatory events in DKD, including the attraction of 
leukocytes to the glomerulus [9]. RAGE is known to activate 
NF-κB, a central transcription factor that elevates expression 
of a variety of cytokines and chemokines and is up-regulated 
by SAA in vitro [3, 10]. NF-κB has been directly implicated in 
contributing to DKD through the promotion of macrophage 
infiltration in kidneys of diabetic mouse models [11]. Indeed, 
human patients with DKD showed a direct correlation of 
activated NF-κB levels in peripheral blood mononucleocytes 
compared to control subjects. In addition, NF-κB-controlled 
promoters are up-regulated in patients with DKD [12, 13]. 
Podocytes exposed to SAA are potential intermediaries for 
NF-κB-mediated inflammation in DKD, which parallels 
other recent findings showing that podocytes produce 
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inflammatory mediators that contribute to self-injury by 
autocrine mechanisms [3, 14, 15].  
Exposure of podocytes to SAA induces a major 
inflammatory response triggering NF-κB-mediated 
transcription of a wide variety of cytokines and chemokines, 
including SAA itself [3]. A repercussion of 
AGE/RAGE-mediated up-regulation of SAA is that SAA 
could be a source of persistent diabetes-induced chronic 
inflammation in the kidney through a forward-feeding 
autocrine loop (Figure 1) [16]. We hypothesize that such a 
feed-forward loop may be a manifestation of 
epigenetic-independent “metabolic memory,” arising from 
aberrant glycemic metabolism resulting in perpetual 
inflammation via SAA activation. Thus, even with 
restoration of normoglycemia and dietary interventions to 
reduce pathological metabolites such as AGE, the 
inflammatory cycle may persist unabated.  
SAA-induced expression of pro-inflammatory factors 
Our research demonstrated that several classes of proteins 
were up-regulated by exposure to SAA in cultured podocytes 
[3]. Several of these have been directly implicated in 
DKD-related inflammation. One class is the CC chemokine 
family. Perhaps the most well-known is monocyte 
chemoattractant protein-1 (MCP-1, or Ccl2). One of the 
functions of MCP-1 is to stop rolling monocytes by arresting 
them to vascular endothelium under blood flow conditions, 
indicating that increased production of MCP-1 in cells 
promotes accumulation of monocytes in tissues [17]. MCP-1 
has been shown to correlate with macrophage accumulation 
and kidney injury in a diabetic mouse model [18]. Subsequent 
studies have shown that RAGE-induced MCP-1 contributes 
to initiation and progression of kidney damage in diabetic 
mice and also correlates with advanced tubulointerstitial 
lesions in human DKD [19-22].  
Several other CC chemokines are also up-regulated in 
podocytes exposed to SAA [3]. Like MCP-1, the chemokine 
RANTES or Ccl5 stops rolling monocytes attached to 
vascular endothelium under flow conditions [23]. RANTES is 
known to be expressed in the kidney of nephritic mouse 
models, recruits T-cells and initiates other immune responses, 
causing injury to tissues [24]. Macrophage inflammatory 
protein-3-alpha (MIP-3 or Ccl20) is up-regulated in proximal 
tubular cells under high-glucose conditions and appears to be 
dependent on transforming growth factor-β1, known to play 
a key role in regulating inflammation and fibrosis under 
diabetic conditions [25].  
Members of the CXC chemokine family are also 
Figure 1. Model of SAA-induced inflammation response. Exposure to diabetes-like conditions causes increased production of SAA by 
key kidney cells, including podocytes, mesangial cells, and tubular epithelial cells. In turn, SAA induces expression of a host of chemokines 
that recruit leukocytes, including monocytes, neutrophils, T-cells, and dendritic cells to the glomerulus. 
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Table 1. SAA-induced chemokines and known target cells 















up-regulated by exposure of podocytes to SAA [3]. One of 
these is epithelial-derived-neutrophil-activating protein 
(ENA-78 or Cxcl5). Increased expression of ENA-78 in the 
tubular epithelium has recently been shown to promote 
neutrophil accumulation and contribute to kidney damage in 
kidneys of mice with glomerulonephritis [26]. Furthermore, 
human subjects with type 2 diabetes and DKD have 
increased urinary levels of ENA-78 compared to non-diabetic 
patients with other kidney diseases, suggesting that ENA-78 
specifically contributes to inflammation in DKD [27]. Other 
members of the CxC family that are also up-regulated in 
podocytes by SAA include: Cxcl1, Cxcl2, Cxcl3 and Cxcl11 
[3]. Atherosclerotic plaques are a known source of elevated 
SAA expression, and the receptor CxcR2, whose ligands 
include Cxcl1, 2, 3, and 5, mediates macrophage 
accumulation in these plaques [28, 29]. Cxcl1 is 
transcriptionally up-regulated in kidneys of mice and humans 
with DKD, while Cxcl2 has been implicated in protein kinase 
Cβ-mediated kidney damage in diabetic mice [30-32]. Cxcl11 
has also been shown to be up-regulated in the 
tubulointerstitium of people with DKD [32]. This ligand binds 
the CxcR3 receptor, which has been found to be expressed 
on mesangial cells in people with glomerulonephritis, and is 
thought to be involved in mesangial cell proliferation.[33] 
Blocking this receptor inhibited leukocyte recruitment under 
inflammatory conditions [34]. SAA also promotes chemotaxis 
of monocytes and dendritic cells by activating a synergistic 
CC and CxC chemokine axis [35]. Therefore, it is likely these 
chemokines work to facilitate leukocyte recruitment and 
mediate SAA-related inflammation in the kidney. 
In addition to leukocytic chemokines, other 
pro-inflammatory factors associated with diabetic kidney 
injury are expressed in SAA-exposed podocytes [3]. 
Complement component 3 (C3) plays a central role in 
complement activation by both the classical and alternate 
pathways. There is clear consensus that the dysregulation of 
the alternate complement pathway, leading to increased 
deposition of C3 without immunoglobulins in the glomerulus, 
is involved in pathogenesis of a class of kidney diseases 
termed C3 glomerulopathy [36]. In addition to classical C3 
production by the liver and mononuclear cells, we recently 
discovered that C3 is expressed by podocytes and markedly 
up-regulated by SAA exposure [3]. Moreover, 
hyperglycemia-dependent glomerular C3 deposition occurred 
concurrently with development and progression of 
glomerular injury in the db/db mouse model of DKD [18]. 
Notably, these data in experimental models are corroborated 
by transcriptomic data that demonstrate increased C3 
expression in kidneys of humans with DKD [32].  
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SAA and local tissue inflammation  
The production of numerous pro-inflammatory factors by 
kidney cells exposed to SAA may be a significant contributor 
to tissue inflammation. As different cytokines and 
chemokines attract different cell-types, the myriad factors we 
found to be increased in the podocyte response to SAA 
exposure are likely to result in accumulation of different cell 
types, including monocytes, neutrophils, T-cells, and 
dendritic cells in the glomerulus and tubulointerstitium 
(Table 1 and Figure 1). A recent study in SAA3 knockout 
mice has been particularly enlightening and provides 
evidence to support our hypothesis that SAA is a major 
contributor to local inflammation and leukocyte recruitment. 
SAA3 knockout (SAA3-/-) C57BL/6 mice fed a 
pro-inflammatory high-fat, high-sucrose diet showed 
decreased expression of MCP-1 and also the inflammatory 
mediator tumor necrosis factor in visceral adipose tissue [37]. 
Additionally, macrophage accumulation in visceral adipose 
tissue was attenuated [37]. Although data on the kidneys of 
these mice were not reported, these results support the 
general concept that SAA can increase local tissue 
inflammation and macrophage recruitment. 
Conclusions 
It is well established that expression of chemoattractant 
factors and accumulation of leukocytes in kidney tissue are 
major contributors to DKD. Given our recent findings 
showing elevated SAA in the blood and kidney tissue 
(glomerular and tubulointerstitial compartments) of patients 
with DKD, along with our data demonstrating that SAA 
induces robust expression of a host of chemoattractant 
molecules in podocytes, it is likely that SAA promotes 
inflammation in DKD. We propose the following conceptual 
model: Diabetes results in production of serum amyloid A in 
kidney cells via an AGE-RAGE signaling pathway. Local 
production of SAA results in production of chemoattractant 
and pro-inflammatory factors including SAA itself. The 
eventual result is a feed-forward signaling loop of SAA that 
perpetuates autocrine expression by podoyctes, leading to 
continuing RAGE activation, leukocyte recruitment, and 
inflammation in the diabetic kidney (Figure 1). Future 
therapies targeting SAA may attenuate a key mediator in the 
production of inflammation, providing a promising avenue to 
reduce inflammation and preserve the kidney in diabetes.  
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